GRCE · ISSUER CIK 1444192
Grace Therapeutics, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 2 Grace Therapeutics, Inc. insiders reported $774K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Opaleye Management Inc. (10% Owner), with $560K.
↗2 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. No open-market sales in the window.
$774KInsider buying
$0.00Insider selling
+$774KNet open-market
Oct 26, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 26, 202618:06 | Oct 26, 2026from Oct 22, 2026 | GRCE | 10% Owner | P · Buy | $1.81 | +87,801 | 3,036,411 | +3% | +$159K | -22.5% | +11.3% |
| Oct 21, 202618:06 | Oct 19, 2026 | GRCE | 10% Owner | P · Buy | $1.88 | +4,256 | 2,948,610 | +0% | +$8K | -22.6% | +6.9% |
| Oct 16, 202620:42 | Oct 16, 2026from Oct 14, 2026 | GRCE | 10% Owner | P · Buy | $1.92 | +71,065 | 2,944,354 | +2% | +$136K | -22.4% | +4.9% |
| Oct 13, 202617:45 | Oct 12, 2026from Oct 8, 2026 | GRCE | 10% Owner | P · Buy | $2.03 | +14,632 | 2,873,289 | +1% | +$30K | -17.9% | -0.9% |
| Oct 5, 202618:46 | Oct 5, 2026from Oct 1, 2026 | GRCE | 10% Owner | P · Buy | $2.05 | +60,490 | 2,858,657 | +2% | +$124K | -19.1% | -1.8% |
| Oct 1, 202616:30 | Sep 29, 2026 | GRCE | 10% Owner | P · Buy | $2.09 | +7,849 | 2,798,167 | +0% | +$16K | -17.4% | -3.8% |
| Sep 23, 202618:19 | Sep 23, 2026from Sep 21, 2026 | GRCE | 10% Owner | P · Buy | $2.10 | +15,089 | 2,855,318 | +1% | +$32K | -17.0% | -4.3% |
| Sep 10, 202616:05 | Sep 9, 2026from Sep 8, 2026 | GRCE | 10% Owner | P · Buy | $2.09 | +15,229 | 2,775,229 | +1% | +$32K | -17.2% | -4.0% |
| Sep 10, 202607:30 | Sep 9, 2026 | GRCE | Chief Executive Officer, Director | P · Buy | $2.14 | +100,000 | 121,357 | +468% | +$214K | -15.4% | -6.1% |
| Aug 19, 202607:44 | Aug 14, 2026 | GRCE | 10% Owner | P · BuyLate 5d | $2.09 | +11,608 | 2,760,000 | +0% | +$24K | -22.5% | -3.6% |